Research & Development

Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment

Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use Catalent’s proprietary Zydis orally disintegrating tablet (ODT) technology

Breaking News

Linde expands krypton and xenon facility

The new complex for the production and filling of these noble gases is the most advanced of its kind and one of the largest in the world

Cambrex completes Snapdragon Chemistry acquisition

The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing

Hovione recognised as a “top employer” for 2023

The Top Employers Institute program certifies organisations based on the participation and results of their HR best practices survey

Personalised medicine: the future of the life sciences industry

Creating medicines that are specific to individual patients requires a lot of data that must be both available and secure, reports Greg Hookings, D...

Catalent signs development deal with Ethicann for new fast-dissolve cannabinoid treatment

Catalent and Canadian/US cannabinoid drug therapy company Ethicann Pharmaceuticals have executed a development and license agreement that will use...

SciMed releases sustainability-focused whitepaper

New whitepaper explores how the lab industry can improve sustainability in ways that improve experimental output and save money

How soon is too soon to consider market access strategies for my specialty drug?

The answer is that it’s never too soon, advises Craig Caceci, Managing Director at Terebellum. In fact, he says, if you want to ensure your product...

Host cell protein analysis: strategies to improve sensitivity and reproducibility

Given that the US FDA approved 25 new cellular and gene therapy products in 2022, gene-based vaccines and therapeutics have now entered the mainstr...

Get ahead of the curve in 2023 with a subscription

Keep abreast of significant pharmaceutical developments around the world

Lilly and ProQR to expand RNA editing collaboration

New agreement supports the discovery and development of additional assets directed toward high conviction targets utilising ProQR’s Axiomer technology

Indena: a full-service provider of APIs, HPAPIs and cGMP contract development and production services

Indena is well known in the naturally derived molecule space with experience gained during its 100-year history. At the same time, the company has...

Overcoming hurdles in the biopharmaceutical pipeline with advanced analytics

In conversation with Nick Pittman and Magnus Wetterhall, both Global Marketing Managers, Bioprocessing, at Waters Corporation, Dr Kevin Robinson ex...

Stablepharma closes series A funding round to progress fridge-free vaccines and mRNA/LNP stabilisation technologies

Stablepharma, the fridge-free vaccine company closed their series A funding round having secured £5.2 million with lead investors Hamilton Portfoli...

Enabling oligonucleotide therapeutics with precision targeting methods

Oligonucleotides are a rapidly growing class of therapeutics. This modality appears to offer highly favourable therapeutic characteristics such as...

Research shows over half drug development professionals feel undermined by regulations

Regulations are shown to slow down the digital transformation for most drug development companies

Where Zymergen went wrong: a biomanufacturing perspective for synthetic biology

After riding reinvigorated attention and investment in the recent past, the biotechnology market has taken a bit of beating so far this year. Nusqe...